| Speaker: |
|
Dr. Tanveer Tabish
Group Leader in Cardiovascular Nanotherapeutics,
Radcliffe Department of Medicine,
University of Oxford, United Kingdom
Abstract:
Nitric oxide (NO) is a key endogenous signalling molecule produced by vascular endothelial cells, crucial for vascular homeostasis. Impaired NO bioavailability is a hallmark of cardiovascular diseases. The lack of spatial and temporal control in systemic NO donors leads to off-target effects and limited therapeutic precision. To address these limitations, we developed nanomaterial-based platforms for controlled and targeted NO delivery. Porous graphene oxide nanosheets functionalised with cysteamine generate S-nitrosated carriers capable of sustained NO release at physiological levels, mimicking endothelial function and selectively promoting endothelial proliferation while inhibiting smooth muscle cell growth via NO–cGMP signalling. Building on this, pH-responsive dipeptide–graphene hybrids enable controlled NO storage and release, enhancing delivery in acidic environments. Extending this approach to subcellular targeting, mitochondria-targeted graphene oxide platforms functionalised with triphenylphosphonium deliver NO directly to cardiac mitochondria, modulating respiration, reducing oxidative stress, and improving cell survival during ischaemia–reperfusion. These results highlight graphene-based nanomaterials as promising platforms for localised and sustained NO delivery in cardiovascular therapy.
Bio:
Dr. Tanveer Tabish is Group Leader in Cardiovascular Nanotherapeutics at the Radcliffe Department of Medicine, University of Oxford. His research integrates materials science, chemical biology, and biomedical engineering to develop advanced biomaterials for cardiovascular medicine. His group specialises in designing and functionalising nanostructures for targeted drug delivery, especially nitric oxide–releasing nanomedicines for cardiovascular regeneration. They aim to build responsive delivery systems that adapt to complex biological environments and restore vascular homeostasis. His group explores how redox balance controls cardiovascular health and disease and how therapeutic gases such as nitric oxide can be hitched through nanomedicine to modulate vascular function, mitochondrial activity and inflammatory pathways. Dr. Tabish has published over 60 papers, holds four patents, and has received the Larry Hench Young Investigator Prize. His work is funded by the British Heart Foundation, Wellcome Trust, Royal Society, Cancer Research UK, and EPSRC.
Details
|
| Venue: |
|
Seminar Room 4,
G/F, Laboratory Block,
21 Sassoon Road,
Pokfulam,
Hong Kong SAR, China
We look forward to seeing you at the seminar
For enquiries, please contact us at esther09@hku.hk
|
